CTLA4 and neoplasm: Combining ICIs with chemotherapy has shown synergistic anti-tumor effects, supporting the rationale for combining chemotherapy with dual immune checkpoint blockade (anti-CTLA-4 and anti-PD-1) in solid tumors (30, 31).